Cubist's revenues up by 46% in the first half
This article was originally published in Scrip
CubistPharmaceuticals' revenues in the second quarter were $101.8 million, virtually all from the lipopeptide Gram-positive antibiotic Cubicin (daptomycin), whose sales were $101.4 million, up 46% on the same period last year. Total half-year revenues were $190 million. The company also markets the carbapenem antibiotic Merrem iv (meropenem), in the US, following an agreement with AstraZeneca concluded in February.